BAYADA's $17M FCA settlement reframes HHA acquisitions as kickback risk

The BAYADA Home Health Care settlement, $17 million to resolve False Claims Act allegations, is structurally interesting beyond its dollar amount. The DOJ alleged BAYADA's purchase of two HHAs from an Arizona retirement-home operator constituted illegal remuneration for referrals — an Anti-Kickback Statute violation expressed through an acquisition price.

What the DOJ alleged

The retirement-home operator referred substantial Medicare patients to its own HHAs. BAYADA acquired those HHAs at a price the DOJ alleged was above fair market value. The theory: the overpayment was, effectively, payment for the referral stream the operator could continue to direct to BAYADA going forward.

The settlement does not establish liability — BAYADA didn't admit wrongdoing — but the DOJ's willingness to bring the theory to settlement signals enforcement appetite for this structure.

Why this matters for mid-market HHAs

Tuck-in acquisitions are the standard growth path for mid-market HHAs. You buy a smaller agency in an adjacent market, fold their patients and clinicians into your organization, and capture the operating leverage. Most of those deals involve sellers who refer patients — referring physicians, retirement community operators, hospital partners, even other agencies.

The BAYADA theory says: if you overpay for the agency you're buying, and the seller is a referral source, the overpayment itself can be characterized as a kickback regardless of how the deal documents are structured. "We paid above book value because of growth potential" doesn't necessarily insulate you.

What changes in your acquisition process

1. Independent fair-market-value opinion on every deal. Not "our CFO modeled it." A third-party valuation expert, with documented methodology, in writing.
2. Anti-Kickback safe-harbor analysis on the deal structure. Standard safe harbors (employment, isolated transaction, fair market value, etc.) need to be specifically applied to the facts of your deal.
3. Document the operating rationale separately from any referral relationship. "We paid X because the agency has Y patients, Z clinicians, P EBITDA, and operates in Q market we wanted to enter" is the defensible narrative. "We paid X because the seller will keep sending us patients" is the indefensible one.
4. Confirm the seller's referral pipeline can transfer cleanly. If the deal premise depends on the seller continuing to refer, the deal structure itself is exposed.

What this won't change

Roll-ups will continue. The home health space remains heavily fragmented and consolidation is the natural arc. What the BAYADA settlement changes is the legal hygiene around individual deals — the days of "we paid 8x for a 5x agency because of strategic value" without a fair-market-value opinion are over.

What we built for this

Carelytic doesn't do M&A advisory — but we do support the operational integration. Multi-tenant architecture means a parent agency can onboard an acquired agency as a separate tenant inside the same Carelytic environment, preserve the acquired agency's data lineage and audit trail, and consolidate reporting at the parent level. Implementation that used to take weeks of data migration now happens through our auto-detecting onboarding (20 of 24 tasks auto-complete from app state).

The pattern to keep in mind: as enforcement gets more sophisticated, deal hygiene matters more. The agencies acquiring smartly in CY2026 will be the ones with FMV opinions on file before the wire transfers.